Publikationen, an denen er mitarbeitet DAVID NAVARRO ORTEGA (22)

2022

  1. Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients

    Scientific Reports, Vol. 12, Núm. 1

  2. Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty® COVID-19 vaccine

    Journal of Infection

  3. SARS-CoV-2-reactive IFN-γ-producing CD4+ and CD8+ T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients

    Scientific reports, Vol. 12, Núm. 1, pp. 14271

2021

  1. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

    Nature, Vol. 595, Núm. 7869, pp. 707-712

  2. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 5, pp. 972-977

  2. Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide

    Bone Marrow Transplantation

2019

  1. Missing cases of herpes simplex virus (HSV) infection of the central nervous system when the Reller criteria are applied for HSV PCR testing: A multicenter study

    Journal of Clinical Microbiology, Vol. 57, Núm. 2

2018

  1. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) proteomic profiling of cerebrospinal fluid in the diagnosis of enteroviral meningitis: a proof-of-principle study

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 37, Núm. 12, pp. 2331-2339

2017

  1. Assessing the risk of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma

    Journal of General Virology, Vol. 98, Núm. 7, pp. 1855-1863

2014

  1. Active cytomegalovirus infection is not a risk factor for Epstein-Barr virus DNAemia in the allogeneic stem cell transplantation setting

    Clinical Transplantation

2013

  1. Need to evaluate the performance of real-time PCR assays for the quantitation of cytomegalovirus DNA load in lower respiratory tract specimens

    Critical Care

2011

  1. Becton Dickinson Directigen EZ Flu A+B assay in the diagnosis of pandemic influenza A H1N1 2009 virus infection in adult patients

    Influenza and other Respiratory Viruses

2008

  1. Enumeration of cytomegalovirus-specific interferong CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection

    Haematologica

2006

  1. Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines in human immunodeficiency virus-1-infected individuals

    Clinical Microbiology and Infection, Vol. 12, Núm. 6, pp. 555-560

2004

  1. Assessment of human cytomegalovirus specific T cell immunity in human immunodeficiency virus infected patients in different disease stages following HAART and in long-term non-progressors

    Journal of Medical Virology, Vol. 74, Núm. 3, pp. 382-389

  2. Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART

    Journal of Clinical Virology, Vol. 29, Núm. 4, pp. 308-314

2002

  1. Application of a 5-bromo-2′-deoxyuridine ELISA for measuring the lymphoproliferative response to human cytomegalovirus in HIV-1-infected patients

    Journal of Virological Methods, Vol. 105, Núm. 2, pp. 247-251

2001

  1. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine

    Journal of Medical Virology, Vol. 65, Núm. 1, pp. 178-184

2000

  1. Early neutralizing and glycoprotein B (gB)-specific antibody responses to human cytomegalovirus (HCMV) in immunocompetent individuals with distinct clinical presentations of primary HCMV infection

    Journal of Clinical Virology, Vol. 16, Núm. 2, pp. 113-122